Immune Responses to an Oral Typhoid Vaccine Strain That Is Modified to Constitutively Express Vi Capsular Polysaccharide
Carol O. Tacket(University of Maryland, Baltimore), Myron M. Levine(University of Maryland, Baltimore), Marcelo B. Sztein(University of Maryland, Baltimore), Sofie Livio(University of Maryland, Baltimore), Marcela F. Pasetti(University of Maryland Global Campus)
Cited by 72
Related Papers
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
|PubMed|1999|1.3k
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
|Nature|1987|503
Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta (IL-1β), IL-6, IL-8, IL-10, Tumor Necrosis Factor Alpha, and IL-12(p70) in Malian Children with Severe<i>Plasmodium falciparum</i>Malaria and Matched Uncomplicated Malaria or Healthy Controls
|Infection and Immunity|2004|447
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
|Nature Reviews Microbiology|2007|372
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans
|Infection and Immunity|1997|251